IL-6 levels are elevated in the adipose tissues of patients with diabetes mellitus or obesity, particularly in those with MS symptoms, suggesting that IL-6 could be used as a prognostic indicator for MS and cardiovascular dysfunction. This evidence concerns the gene IL6 and obesity disorder.